Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Most U.S. stocks climbed Thursday, but the worst drop for UnitedHealth Group in a quarter of a century kept Wall Street in ...

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in US trade ...

U.S. stocks saw mixed movements as UnitedHealth plunged 22% after a weak earnings report, dragging the Dow down 527 points.

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter of a century kept Wall Street in check. The S&P 500 edged up 0.1% Thursday even ...

The UnitedHealth slide weighed heavily on the Dow, which fell 527 points, or 1.3%.

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled ...